HC Wainwright downgraded shares of Corium International (NASDAQ:CORI) from a buy rating to a neutral rating in a report released on Monday morning, MarketBeat Ratings reports. They currently have $13.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. ValuEngine raised Corium International from a hold rating to a buy rating in a report on Friday, August 10th. Cantor Fitzgerald reaffirmed a buy rating and issued a $14.00 target price on shares of Corium International in a report on Friday, August 10th. Zacks Investment Research raised Corium International from a sell rating to a hold rating in a report on Tuesday, August 14th. Finally, BidaskClub raised Corium International from a strong sell rating to a sell rating in a report on Friday, August 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Corium International has a consensus rating of Hold and a consensus target price of $12.80.
Shares of Corium International stock opened at $12.57 on Monday. Corium International has a 52 week low of $7.17 and a 52 week high of $13.93. The company has a current ratio of 7.61, a quick ratio of 7.47 and a debt-to-equity ratio of 2.83.
In other Corium International news, CEO Peter D. Staple sold 76,341 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $8.81, for a total transaction of $672,564.21. Following the sale, the chief executive officer now directly owns 362,316 shares of the company’s stock, valued at $3,192,003.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph J. Sarret sold 3,565 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The disclosure for this sale can be found here. Insiders sold 3,752,412 shares of company stock worth $46,538,512 over the last ninety days. Insiders own 30.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CORI. Engineers Gate Manager LP bought a new stake in Corium International during the second quarter worth approximately $215,000. Alps Advisors Inc. bought a new stake in Corium International during the second quarter worth approximately $420,000. Citadel Advisors LLC bought a new stake in Corium International during the first quarter worth approximately $455,000. Schwab Charles Investment Management Inc. increased its stake in Corium International by 40.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 58,309 shares of the biopharmaceutical company’s stock worth $468,000 after acquiring an additional 16,900 shares during the last quarter. Finally, Private Capital Advisors Inc. bought a new stake in Corium International during the second quarter worth approximately $521,000.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Recommended Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.